Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma (FIZZ)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Bayer
Information provided by:
Christie Hospital NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT01493479
First received: December 14, 2011
Last updated: December 15, 2011
Last verified: December 2011

December 14, 2011
December 15, 2011
June 2007
September 2015   (final data collection date for primary outcome measure)
  • Overall response rate [ Time Frame: Assessed 3 months post treatment ] [ Designated as safety issue: No ]
    According to Cheson criteria to standardize response for non-Hodgkin's lymphoma, 1999.
  • Combined Complete Response rate [ Time Frame: Assessed 3 months post treatment ] [ Designated as safety issue: No ]
    According to Cheson criteria to standardize response for non-Hodgkin's lymphoma, 1999.
  • Partial Response Rate [ Time Frame: Assessed 3 months post treatment ] [ Designated as safety issue: No ]
    According to Cheson criteria to standardize response for non-Hodgkin's lymphoma, 1999.
Same as current
Complete list of historical versions of study NCT01493479 on ClinicalTrials.gov Archive Site
  • Time to disease progression [ Time Frame: Assessed 3 months post treatment, repeated assessment up to 5 years follow-up ] [ Designated as safety issue: No ]
  • Response duration [ Time Frame: Assessed 3 months post treatment, repeated assessment up to 5 years follow-up ] [ Designated as safety issue: No ]
    To be assessed for patients achieving a response, including assessment of overall survival and time until next treatment.
Same as current
Not Provided
Not Provided
 
Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma
Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin)

90Y Ibritumomab tiuxetan (zevalin) has demonstrated consistently high response rates in patients who have received previous treatment for lymphoma. More than two-thirds of the patients who achieve CR go on to experience durable remissions lasting for years. Despite these highly promising clinical results with radioimmunotherapy (RIT) in relapsed follicular lymphoma there is very little data using RIT in previously untreated follicular lymphoma. The objective of this trial is to evaluate the safety and efficacy of two fractions of Zevalin in patients with previously untreated follicular lymphoma in a Phase II study.

Not Provided
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Follicular Lymphoma
  • Drug: 90Y Ibritumomab tiuxetan
    2 x iv infusions of 11.1 MBq/kg. 1st infusion at week 1, 2nd during weeks 9-13. 2nd infusion may be reduced to 7.4MBq/kg in the case of grade 3 haematological toxicity following the 1st infusion.
    Other Name: Zevalin
  • Drug: Rituximab

    All patients receive 2 x iv infusions of 250 mg/m2 Rituximab given 7-8 days apart prior to each zevalin infusion. The 2nd rituximab infusion is given immediately prior to Zevalin.

    In addition patients with greater than 20% bone marrow involvement at screening receive rituximab pretreatment prior to entering the main treatment phase of the trial, consisting of 4 x weekly iv doses of rituximab(375 mg/m2). This is followed by a repeat bone marrow biopsy, bone marrow involvement must have fallen to <= 20% to enter the main treatment phase of the trial.

    Other Name: Mabthera
Experimental: Fractionated Initial Zevalin
Interventions:
  • Drug: 90Y Ibritumomab tiuxetan
  • Drug: Rituximab
Illidge TM, Mayes S, Pettengell R, Bates AT, Bayne M, Radford JA, Ryder WD, Le Gouill S, Jardin F, Tipping J, Zivanovic M, Kraeber-Bodere F, Bardies M, Bodet-Milin C, Malek E, Huglo D, Morschhauser F. Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. J Clin Oncol. 2014 Jan 20;32(3):212-8. doi: 10.1200/JCO.2013.50.3110. Epub 2013 Dec 2.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
76
September 2015
September 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must have a histologically confirmed CD20 +ve follicular lymphoma grades I to IIIa.
  • Patients with at least one of the following symptoms requiring initiation of treatment: (as outlined by the modified BNLI/GELF criteria below)

    • Nodal mass > 7cm in its greater diameter
    • B symptoms
    • Elevated serum LDH or beta2-microglobulin
    • involvement of at least 3 nodal sites (each with a diameter > 3 cm)
    • symptomatic splenic enlargement
    • compressive syndrome
  • Patients must have an ECOG performance status less than or equal to 2 and an anticipated survival of at least 6 months.
  • Patients must have an absolute granulocyte count of above 1,500/mm3, and a platelet count of above 100,000/mm3 post 4 weeks of unlabelled Rituximab. A hemoglobin >= 8.0 g/dl
  • Patients must have adequate renal function (defined as calculated creatinine clearance > 30 ml/mn), hepatic function (defined as total bilirubin <1.5 times upper limit of normal), and hepatic transaminases (defined as AST <5 times upper limit of normal)
  • Patients must have given informed consent prior to study entry.

Exclusion Criteria:

  • Patients with a mean of >20% of the intratrabecular marrow space involved with lymphoma on bone marrow biopsy following induction Rituximab therapy.
  • Transformed follicular lymphoma and discordant lymphoma
  • Patients with active obstructive hydronephrosis.
  • Patients with initial disease bulk greater than 10cm.
  • Patients with evidence of active infection requiring i.v. antibiotics at the time of study entry.
  • Patients with congestive heart failure stage III or IV of NYHA classification, myocardial infraction or unstable angina within 6 months or other serious illness that would preclude evaluation.
  • Patients with left VEF < 40%
  • Patients with large pleural or peritoneal effusions.
  • Patients with known HIV infection or active HBV (HbsAg positivity) or HCV infection.
  • Known Hypersensitivity to murine antibodies or proteins
  • Patients who are pregnant or breast-feeding. Male and female patients must agree to use effective contraception for 12 months following 90Y-ibritumomab tiuxetan antibody therapy.
  • Patients with prior malignancy other than lymphoma, except for adequately-treated skin cancer, cervical cancer in situ, or other cancer for which the patient has been disease-free for 5 years.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France,   United Kingdom
 
NCT01493479
06_DOG05_33
Yes
Not Provided
Christie Hospital NHS Foundation Trust
Bayer
Principal Investigator: Timothy Illidge, Prof The Christie NHS Foundation Trust
Christie Hospital NHS Foundation Trust
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP